UPDATE: These are the only 9 stocks Morningstar is fully bullish on
Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...
As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.
The corporate bond market will probably struggle to return much above break-even in 2014.
Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.